Interleukin-17 plays a critical role in the acute rejection of intestinal transplantation

Jian-Jun Yang, Fan Feng, Liu Hong, Li Sun, Meng-Bin Li, Ran Zhuang, Feng Pan, Ying-Mei Wang, Wei-Zhong Wang, Guo-Sheng Wu, Hong-Wei Zhang

METHODS: We detected the expression of helper T cell 17 (Th17) cells in biopsy specimens from 3 cases of living small bowel transplantation in our department through immunofluorescence stain. We then established a rat heterotopic small bowel transplantation model. The rats were sacrificed on the 1st, 2nd, 3rd, 5th, and 7th d after small bowel transplantation. The degree of transplantation rejection in rat intestine graft was examined through hematoxylin eosin (HE) stain, and the expression of Th17 cells in rat intestine graft were detected through immunofluorescence stain. In addition, the recipient rats undergoing intestinal transplantation were administrated with mouse-anti-rat IL-17 monoclonal antibody (mAb), and the survival of rats was analyzed. The recipient rats which received mouse-anti-rat IL-17 mAb treatment were sacrificed on the 1st, 2nd, 3rd, 5th, and 7th d after small bowel transplantation. The degrees of transplantation rejection and the expression of Th17 cells in rat intestine graft were detected through HE and immunofluorescence stain. The expression of IL-17, IL-1β, tumor necrosis factor receptor-α (TNF-α), IL-6, and IL-8 in the intestine graft serum were also detected.

RESULTS: The expressions of Th17 cells ran parallel with the degree of acute rejection in human intestine grafts. The intestine graft rejection of rats was aggravated with prolonged duration after intestinal transplantation, and the expressions of Th17 cells were also correlated with the degree of acute rejection in rat intestine grafts. Administration of mouse-anti-rat IL-17 mAb prolonged the survival of rats after small bowel transplantation (P < 0.001). Furthermore, we found that the administration of mouse-anti-rat IL-17 mAb significantly decreased the intensity of CD4+IL-17+ Th17 cells in intestine grafts on the 2nd, 3rd, 5th, and 7th d (97.22 ± 4.05 vs 12.45 ± 2.02 on the 7th d, P < 0.0001), and suppressed the severity of acute rejection. The expression of IL-17 in the intestine graft declined after mouse-anti-rat IL-17 mAb administration on the 2nd, 3rd, 5th, and 7th d. However, there was no significant difference in the survival of rats among groups (P > 0.05).

Abstract

AIM: To investigate the role of interleukin (IL)-17 in small bowel allograft rejection.
5th, and the 7th d (0.88 ± 0.03 vs 0.35 ± 0.02 on the 7th d, P < 0.0001). We also detected the IL-17 serum level and found that the IL-17 level reduced from the 1st d to the 7th d (6.52 ± 0.18 ng/mL vs 2.04 ± 0.15 ng/mL on the 7th d, P < 0.0001). No significant difference in the level of IL-17 mRNA in the intestine graft was identified between the two groups. The levels of IL-1β, TNF-α, IL-6, and IL-8 mRNA in the intestine graft after the administration of mouse-anti-rat IL-17 mAb were also tested. We found that on the 3rd, 5th, and 7th d after intestinal transplantation, administration of mouse-anti-rat IL-17 mAb significantly inhibited the levels of IL-1β (12.11 ± 1.16 vs 1.27 ± 0.15 on the 7th d, P < 0.001), TNF-α (27.37 ± 2.60 vs 1.06 ± 0.26 on the 7th d, P < 0.001), IL-6 (21.43 ± 1.79 vs 1.90 ± 0.32 on the 7th d, P < 0.001), and IL-8 (20.44 ± 1.44 vs 1.34 ± 0.20 on the 7th d, P < 0.001) mRNA in the intestine graft.

CONCLUSION: IL-17 may act as a promising and potent target for inhibiting acute rejection after small bowel transplantation.

© 2013 Baishideng. All rights reserved.

Key words: Interleukin-17; Helper T cell 17; Small bowel transplantation; Acute rejection; Monoclonal antibody

Yang JJ, Feng F, Hong L, Sun L, Li MB, Zhuang R, Pan F, Wang YM, Wang WZ, Wu GS, Zhang HW. Interleukin-17 plays a critical role in the acute rejection of intestinal transplantation. World J Gastroenterol 2013; 19(5): 682-691 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i5/682.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i5.682

INTRODUCTION

Small bowel transplantation is a prevailing therapy for short bowel syndrome[1-3]. However, compared with liver[4,5], kidney[6,7], and heart transplantation[8,9], small bowel transplantation has less satisfying effects. The small bowel and mesentery involve redundant lymphoid tissue, which are organs with high immunogenicity prone to inducing severe transplantation rejection. FK506 (Tacrolimus) may inhibit the activation of T cells through suppressing the production of rejection related cytokines, calcium-dependent phosphatase calcineurin, and JNK/p38 pathways[10,11]. FK506 can prevent the aggregation of lymphocytes in the early rejection and chemotaxis of inflammatory cells. But the usage of FK506 after clinical small bowel transplantation may result in severe side effects, such as renal toxicity and neurotoxicity[12].

Recently, the helper T cell (Th)1/Th2 paradigm has been expanded, following the discovery of a third subset of effector T helper cells that produce interleukin (IL)-17 (Th17) and exhibit effector functions[13-15]. On the basis of these studies, investigators proposed that IL-17-producing T cells serve as a distinct T helper cell subset, which are called Th17 cells[16-18]. The primary function of Th17 cells appears to be the clearance of pathogens that are not adequately handled by Th1 or Th2 cells[19]. Th17 cells, as potent inducers of tissue inflammation, have a proven association with the pathogenesis of many experimental autoimmune diseases and human inflammatory conditions[20,21].

In the present study, we reveal that Th17 cells and IL-17 cytokine are expressed in the intestine graft after small bowel transplantation. Furthermore, we found that the level of Th17 cells ran parallel with the degree of rejection. The data clearly indicates that Th17 cells and IL-17 cytokine may play an important role in transplant rejection.

MATERIALS AND METHODS

Patients and specimens

This study was approved by the Ethics Committee of the Fourth Military Medical University. Biopsy specimens embedded in paraffin from 3 cases of living-related small bowel transplantation were collected from Xijing Hospital of Digestive Diseases, Fourth Military Medical University (FMMU) from 1999 to 2003. All clinical information was available. The sections were stained for pathological examination. The brief clinical characteristics of these patients are listed as follows: Patient No. 1 was an 18-year-old boy with a 40 cm intestine who received a 150 cm segment of distal ileum from his father; Patient No. 2 was a 17-year-old boy with a 8 cm intestine who received a 170 cm graft of distal ileum from his father and; Patient No. 3 was a 15-year-old boy with a 10 cm intestine who received a 160-cm graft of distal ileum from his mother. All the recipients underwent different degrees of graft rejection after operation. The first two patients survived, while the third died from acute graft rejection and severe infection.

Mice

Forty inbred male F344/NCrI BR and forty LEW/Crl rats (age: 8 to 12 wk old, weight: 180 to 230 g) were purchased from Vital River Lab Animal Technology Co., Ltd (Beijing, China). Animals were maintained in specific pathogen-free conditions. All animal experiments were approved by the Animal Experiment Administration Commission of FMMU.

Small bowel transplantation

Donors and recipients were intraperitoneally anesthetized with pentobarbital (5 g/L). The small intestine 5 cm distal to the ligament of Treitz was harvested from the donor rats and 20 cm of isolated jejunum, along with mesenteric blood vessels, was prepared for transplantation. The left kidney of the recipient was removed and the infrarenal abdominal aorta isolated. An end-to-side vascular anastomosis was performed between the recipient and donor’s abdominal aorta. The cuffed portal vein was inserted into the left renal vein. The two ends of the small bowel graft were constructed as separate stomas through the left abdominal wall. Detailed procedures were followed as previously...
Histology
Specimens were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned at 4 µm thickness, and stained with hematoxylin and eosin, following standard methods.

Figure 1 Expression levels of helper T cell 17 cells in intestine grafts paralleled with the degree of rejection in human recipients. The paraffin-embedded human intestine tissues after small bowel transplantation were sectioned and stained with hematoxylin eosin (HE), anti-rat-interleukin-17, and anti-rat-CD4 fluorescence antibodies (× 400). A-E: HE staining of intestine graft; F-J: Helper T cell 17 (Th17) immunofluorescence staining of intestine graft; A, F: No acute rejection; B, G: Suspicous acute rejection; C, H: Mild acute rejection; D, I: Moderate acute rejection; E, J: Severe acute rejection; K: Mean fluorescence intensity (MFI) of Th17 expression of intestine graft.

In treatment experiments, the recipient rats in the control group were administrated with mouse-immunoglobulin G (IgG), while the recipient rats in the anti-IL-17 monoclonal antibody (mAb) group were administrated intravenously with 200 µg mouse-anti-rat IL-17 mAb daily during the operation, and on the 1st, 2nd, 3rd, 5th, and 7th d afterwards.
Diagnostic criteria for transplant rejection of human and rat small bowel transplantation

The biopsy specimens of human and rat intestine grafts were stained with hematoxylin eosin (HE), and analyzed by two independent pathologists. The histological degrees for acute intestine graft rejection were divided into four grades: indeterminate for acute rejection, mild acute rejection, moderate acute rejection, and severe acute rejection. The details of the diagnostic criteria for acute intestine graft rejection have been described previously.\[24\]
Yang JJ et al. Role of IL-17 in intestinal transplantation

**Enzyme-linked immunosorbent assay**

Blood from the heart was extracted when the rat was sacrificed. Serum was collected and adopted in order to detect the level of IL-17 with a rat IL-17 enzyme-linked immunosorbent assay kit (ELISA) (Rapidbio, America) by standard procedures. Absorbance was recorded by a spectrophotometer, and was compared between groups.

**Quantitative real time polymerase chain reaction**

Total RNA was extracted from rat intestine grafts with a homogenizer by using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Complementary DNA was prepared with a reverse-transcription kit from TOYOBO (Osaka, Japan). Real-time reverse-transcription polymerase chain reaction (RT-PCR) was performed by using a kit (SYBR Premix EX Taq, Takara) and the ABI PRISM 7500 real-time PCR system, with β-actin as an internal control. Primers used in real-time PCR were as follows, β-actin, forward: CCTCCCTGGAGATCTCTG, reverse: CGCTACCCCTGCTTTG; IL-1β, forward: GCCAACACAGAAATTATTGTAAAGCTT, reverse: TCCACGGCCAAGACATAGGTAGC, tumor necrosis factor receptor-α (TNF-α), forward: CTGTGCCCTACGCTCTTCTCATTC, reverse: TTGGGAGACTTCTCCTCCTTGTTGG; IL-6, forward: GACTGATGTGGTTGTACAGCCACTGTG, reverse: TAGCCACTCTCTCTGACTCTAATCT, IL-8, forward: GCCAACACAGAAATTATTGTAAAGCTT, reverse: CCTGGACCGCCAAGACATAGGTAGC.

**Western blotting**

The total proteins of the intestine graft were extracted and determined according to the manufacturer’s manuals. Proteins were electrophoresed in 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted on a nitrocellulose membrane. The membrane was incubated with rabbit anti-rat IL-17 polyclonal antibody (1:50 dilution; Santa Cruz Biotechnology) and mouse anti-human CD4 mAb (1:100 dilution; Santa Cruz Biotechnology) as the primary antibodies. Goat-anti-rabbit IgG-TR (1:50 dilution; Santa Cruz Biotechnology) and goat-anti-mouse IgG-FITC (1:50 dilution; Santa Cruz Biotechnology) were used as secondary antibodies. We did not compare the staining for IL-17 before and after transplantation, but only selected the paraffin-embedded human intestine mucosa specimens at different transplantation rejection degrees in order to detect the expressions of Th17 cells.

**Immunofluorescence**

The paraffin-embedded human intestine mucosa specimens were sectioned at 4 µm thickness. Immunofluorescence was performed by standard procedures, with rabbit-anti-human IL-17 polyclonal antibody (1:50 dilution; Santa Cruz Biotechnology) and mouse-anti-human CD4 mAb (1:100 dilution; Santa Cruz Biotechnology) as the primary antibodies. Goat-anti-rabbit IgG-TR (1:50 dilution; Santa Cruz Biotechnology) and goat-anti-mouse IgG-FITC (1:50 dilution; Santa Cruz Biotechnology) were used as secondary antibodies. We did not compare the staining for IL-17 before and after transplantation, but only selected the paraffin-embedded human intestine mucosa specimens at different transplantation rejection degrees in order to detect the expressions of Th17 cells.

The negative control sections were used in our immunofluorescence method. We took phosphate buffered solution (PBS) instead of the primary antibodies as a negative control, and adopted rat cardiac allograft specimens as a positive control (data not shown). The methods of the immunofluorescence stain of Th17 in our present study were in accordance with our previous report [25].

**Statistical analysis**

Statistical analysis was performed with the SPSS 16.0 program. Results were expressed as means ± SD. Comparisons between groups were made by the unpaired Student’s t-test. For survival studies, Kaplan-Meier survival curves were generated and a statistical analysis was performed via the log-rank test. P < 0.05 was considered statistically significant.

**RESULTS**

**Expression levels of Th17 cells in intestine graft ran parallel with the degree of rejection.**

To examine the expression of Th17 cells on a human intestine graft, biopsy specimens embedded in paraffin from 4 cases of living small bowel transplantation in our department were collected and stained with HE (Figure 1A-E) and antibodies against IL-17 and CD4 (Figure 1F-J). The density of IL-17+CD4+ Th17 cells was calculated and analyzed by Image-Pro-Plus 5.1 software. As shown in Figure 1K, the density of IL-17+CD4+ Th17 cells increased when the rejection degrees aggravated.

In order to investigate whether Th17 cells exist in rat intestine grafts after transplantation, intestines from F344/NCrl BR were grafted to LEW/Crl rats; the recipi-
ent rats were sacrificed on the 1\textsuperscript{st}, 2\textsuperscript{nd}, 3\textsuperscript{rd}, 5\textsuperscript{th}, and 7\textsuperscript{th} after transplantation, and the expression of Th17 cells in rat intestine grafts were analyzed (Figure 2A-J). In accordance with the findings in human intestine grafts, we found that Th17 cells were located in rat intestine grafts and the degree of Th17 cells corresponded to the severity of transplant rejection (Figure 2K). Taken together, Th17 cells did exist in intestine grafts, and the levels of Th17 cells might relate to the transplant rejection degrees in both human and rat recipients.

**Administration of anti-IL-17 mAb prolonged the survival of rat post-transplantation**

Since IL-17 may play a role in small bowel transplantation rejections, we hypothesized that IL-17 could be considered as a potential target for the treatment of graft rejec-
tion. In order to further demonstrate our hypothesis, the recipients were administrated with mouse-anti-rat IL-17 monoclonal antibody intravenously during, and after, small bowel transplantation, and the survival of recipients were analyzed. We found that administration of anti-IL-17 mAb could significantly prolong the survival of rats after small bowel transplantation (Figure 3).

**Anti-IL-17 mAb administration inhibited transplant rejection of intestine graft**

We further analyzed the effect of anti-IL-17 administration on graft rejections. The administration of anti-IL-17 mAb was proved to effectively inhibit transplant rejection of intestinal grafts in rats post-transplantation by HE staining (Figure 4A-E). Furthermore, we found that the expression of Th17 cells in intestine grafts also dramatically declined (Figure 4F-K), indicating that anti-IL-17 mAb could possibly prolong the survival of recipient rats by inhibiting transplant rejection.

**Anti-IL-17 mAb administration decreased IL-17 expressions in rat**

During and after allotransplantation, recipient rats were administrated with anti-IL-17 mAb. The recipient rats were sacrificed on the 1st, 2nd, 3rd, 5th, and 7th d after transplantation. The expressions of IL-17 in intestine grafts and serum were further detected by western blot and ELISA (Figure 5). In the control group which only received saline administration, the levels of IL-17 protein in the intestine graft and serum were found to have increased post-allotransplantation and run parallel with transplant rejection degrees. In the anti-IL-17 mAb administration group, the expression of IL-17 could also be detected, but the degrees were remarkably lower than the control group. The levels of IL-17 mRNA in the intestine graft in two groups were not significantly different. Therefore, the administration of anti-IL-17 mAb could decrease the IL-17 level in intestine grafts and serum.

**Anti-IL-17 mAb administration decreased expressions of related cytokines**

As shown in Figure 6, the expressions of IL-1β, IL-6, IL-8, and TNF-α mRNA of intestine grafts in the control group were found to increase post-allotransplantation and correlate to transplant rejection degrees. Administration of anti-IL-17 mAb could dramatically decrease the expression of mRNA levels of these cytokines in intestine grafts, compared with the control group.
Th17, known as a distinct lineage of helper T cells from Th1 and Th2, has both a defense role against microbe infection and a pathogenic role in several autoimmune diseases [26]. Th17 cells have been shown to be implicated in allograft rejection of solid organs, such as lung and cardiac transplantation [25,27,28]. Vanaudenaerde et al [27] observed that IL-17 expression increased in bronchoalveolar lavages in patients with acute lung transplantation rejection. The disease-promoting role of Th17 in cardiac allograft rejection was also confirmed, especially in the absence of a Th1 response [25]. Th17 cells not only function in host-versus-graft disease, but also participate in graft-versus-host disease [29-31]. So far, the relationship between Th17 cells and small bowel transplantation has been unclear. In this study, we demonstrated that Th17 cells participated in the development of human and rat small bowel transplantation rejection.

Here we found that Th17 cells existed in intestine grafts with different degrees of acute rejection. Furthermore, we indicated that the density of Th17 cells increased when the rejection degree aggravated, suggesting that it might be related to the transplant rejection degrees in human recipients. Th17 cells were also found to be located in rat intestine grafts, and the degree of Th17 cells correlated with transplant rejection degrees, which was in accordance with the findings in human intestine grafts. These demonstrate that Th17/IL-17 may participate and play a critical role in the graft rejections of small bowel transplantation.

IL-17, secreted by Th17 cells, is a highly inflammatory cytokine with robust effects on stromal cells in many tissues [32,33]. Hsieh et al [34] reported that IL-17 could serve as a predictive parameter for borderline subclinical renal allograft rejection in the future. Itoh et al [35] found that IL-17-deficient recipient mice had decreased allograft inflammatory cell recruitment, and demonstrated that IL-17 contributed to the pathogenesis of chronic allograft rejection. In order to demonstrate the key role of IL-17 in the graft rejection of small bowel transplantation, we utilized mouse-anti-rat IL-17 mAb to treat recipient rats undergoing small bowel transplantation for the first time. Surprisingly, after administration of anti-IL-17 mAb, the acute rejection degrees of recipient rats significantly decreased compared to the control group. The levels of Th17 cells that had infiltrated the intestine graft during anti-IL-17 mAb administration also fell greatly. Administration with anti-IL-17 mAb could extend the survival time of rats undergoing small bowel transplantation. To sum up, IL-17 cytokine could probably be taken as a potent target to treat acute rejection in small bowel transplantation.

**Figure 6** mRNA level of interleukin-1β (A), tumor necrosis factor-α (B), interleukin-6 (C), and interleukin-8 (D) were analyzed by reverse transcriptase polymerase chain reaction. The intestines from inbred F344 were transplanted to LEW rats. The recipient rats were randomly divided into control and anti-interleukin (IL)-17 mAb treated groups. The rats were sacrificed on the 1st, 2nd, 3rd, 5th, and 7th d after transplantation. The mRNA was extracted and quantitative reverse transcriptase polymerase chain reaction was performed. β-actin was considered as an internal control. *P < 0.05, **P < 0.01 vs control group.
transplantation.

The differentiation factors (transforming growth factor beta plus IL-6 or IL-21), the growth and stabilization factor (IL-23), and the transcription factors (signal transducer and activator of transcription 3, related orphan receptor-γ (ROγ), and ROα) were involved in the development of Th17 cells. Mice reconstituted with the bone marrow of ROγ deficient mice showed an impaired Th17 differentiation. The combinations of IL-1β plus IL-6[18] or IL-1β plus IL-23[19] were proposed to be the differentiation factors for human Th17 cells. We found that the expression of IL-1β and IL-6 was significantly decreased after anti-IL-17 mAb administration. Therefore, anti-IL-17 mAb might suppress the expression of IL-1β and IL-6 in rat intestine grafts, and then inhibit the development and activation of Th17 cells. TNF is also induced by IL-17 cytokine. Its expression was found to be reduced after anti-IL-17 mAb administration.

The migration and infiltration of inflammatory cells into intestine grafts requires the expression of chemokines. Chemokine (C-X-C motif) ligand 8 (IL-8), a target of IL-17, is involved in transplant rejections. Compared to the control group, the expression of IL-8 was found to be obviously decreased in intestine grafts treated with anti-IL-17 mAb. This suggests that anti-IL-17 mAb administration might suppress the migration and infiltration of Th17 cells into intestine grafts by decreasing the expression of chemokines.

In conclusion, we have illustrated that Th17 cells might play an important role in human and rat small bowel acute transplantation rejection. The administration of anti-IL-17 mAb could significantly suppress the acute rejection degree of rat intestine grafts and prolong the survival time of recipient rats. IL-17 could be considered as a promising and potent target for inhibiting acute rejection after small bowel transplantation.

**COMMENTS**

**Background**

Small bowel transplantation is a widespread therapy for short bowel syndrome. However, the efficacy of small bowel transplantation is not satisfactory due to severe transplantation rejection. Although administration of FK506 may inhibit the activation of T cells, prevent the aggregation of lymphocytes in early rejection, and restrain the chemotaxis of inflammatory cells, its administration after human small bowel transplantation may cause severe side effects such as renal toxicity and neurotoxicity.

**Research frontiers**

The helper T cell (Th) 17 cell, as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease, is known as a small bowel transplantation rejection. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease.

**Innovations and breakthroughs**

So far, the relationship between Th17 cells and small bowel transplantation has been unclear. Authors demonstrated the presence of Th17 cells in the intestine grafts of humans and rats, and further found that the expression levels of Th17 cells in intestine grafts correlated with the degree of rejection. The authors hypothesized that Th17IL-17 might play a critical role in small bowel transplantation rejection and could be regarded as a potential target for the treatment of graft rejection. They then treated recipient rats with mouse-anti-rat IL-17 monoclonal antibody (mAb) and found that its administration could significantly prolong the survival of rats after small bowel transplantation. Furthermore, the authors found that the expression of Th17 cells in intestine grafts also dramatically declined, indicating that mouse-anti-rat IL-17 mAb may prolong the survival of recipient rats by inhibiting transplant rejections. In the present study, the authors demonstrated that Th17 cells participated in the development of human and rat small bowel transplantation rejection.

**Applications**

The administration of mouse-anti-rat IL-17 mAb could significantly suppress the acute rejection degree of rat intestine grafts and prolong the survival time of recipient rats. IL-17 could be considered as a promising and potent target for inhibiting acute rejection after small bowel transplantation.

**Terminology**

Small bowel transplantation: an operation to replace a diseased or shortened small bowel with a healthy bowel from a donor and a valuable therapy for short bowel syndrome. Transplant rejection: immune system attacks between the transplant recipient and the transplanted organ or tissue, which include host-versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease. Th17 cell: known as a distinct lineage of helper T cells from Th1 and Th2 that has both a defense role versus-graft disease and graft-versus-host disease.

**Peer review**

This is an investigation of the role of IL-17 in acute intestinal transplantation rejection and the administration of anti-IL-17 monoclonal antibodies for the suppression of IL-17 production by Th17 cells in the intestine graft and, as a result, suppression of acute rejection of the intestine graft in both human and rat models. It is a very good work and I hope it is applicable in human subjects undergoing intestinal transplantation.

**REFERENCES**

1 Donohoe CL, Reynolds JV. Short bowel syndrome. Surg 2010; 8: 270-279 [PMID: 20709285 DOI: 10.1016/j.surge.2010.06.004]
2 Tzvetanov IG, Oberholzer J, Benedetti E. Current status of living donor small bowel transplantation. Curr Opin Organ Transplant 2010; 15: 346-348 [PMID: 20445488 DOI: 10.1097/MOT.0b013e32835398a4]
3 Li M, Ji G, Feng F, Song W, Ling R, Chen D, Liu X, Li J, Shi H, Wang W, Zhang H. Living-related small bowel transplantation for three patients with short gut syndrome. Transplant Proc 2008; 40: 3629-3633 [PMID: 19100455 DOI: 10.1016/j.transproceed.2008.06.064]
4 Kamath BM, Olthoff KM. Liver transplantation in children: update 2010. Pediatr Clin North Am 2010; 57: 401-414, table of contents [PMID: 20071044 DOI: 10.1016/j.pcl.2010.01.012]
5 Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology 2010; 51: 1869-1884 [PMID: 20235333 DOI: 10.1002/hep.23595]
6 Freitas MC. Kidney transplantation in the US: an analysis of the OPTN/UNOS registry. Clin Transpl 2011; 1-16 [PMID: 22753907]
7 Huang E, Segev DL, Rabb H. Kidney transplantation in the elderly. Semin Nephrol 2009; 29: 621-635 [PMID: 19806794 DOI: 10.1016/j.semnephrol.2009.07.011]
8 Everly MJ. Cardiac transplantation in the United States: an analysis of the UNOS registry. Clin Transpl 2008; 35-43 [PMID: 19784444]
9 Kruse CD, Helvind M, Jensen T, Gustafsson F, Mortensen SA, Andersen HO. Good long-term survival after paediatric heart transplantation. Dan Med J 2012; 59: A4367 [PMID: 22239842]
10 Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-591 [PMID: 8588225]
11 Kochel I, Strazdala L. [FK506 - binding proteins in the regulation of transcription factors activity in T cells]. Postepy Hig Med Dosw (Online) 2004; 58: 118-127 [PMID: 15070706]
Yang JJ et al. Role of IL-17 in intestinal transplantation.

12 Zhu Y, Wei W, Li Y. FK506 treatment in a long-term chronic rejection rat model of small bowel transplantation. *Clin Invest Med* 2010; 33: E168-E173 [PMID: 20519095]

13 Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. *Nature* 2006; 441: 235-238 [PMID: 16648837 DOI: 10.1038/nature4753]

14 Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the Th(17) lineage. *Nature* 2006; 441: 231-234 [PMID: 16648837 DOI: 10.1038/nature4753]

15 Zhou L, Ivanov II, Spolski R, Min R, Shendure K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs Th(17) cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. *Nat Immunol* 2007; 8: 967-974 [PMID: 17581537 DOI: 10.1038/nii1488]

16 Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med* 2005; 201: 233-240 [PMID: 15657292 DOI: 10.1084/jem.20041257]

17 Park H, Li Z, Yang XO, Chang SH, Nurieva R, Yang JJ, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Loong CC, Lui WY, Chen A, Lin CY. IL-17 ex vivo repletion B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Yuan X. Interferon-gamma regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease. *Am J Respir Crit Care Med* 2009; 178: 379-388 [PMID: 18517101 DOI: 10.1164/rccm.200711-1648OC]

18 Wynn TA. Th17: a giant step from Th1 and Th2. *Nat Immunol* 2005; 6: 1133-1141 [PMID: 16200068 DOI: 10.1038/nature04744]

19 Oukka M. Th17 cells in immunity and autoimmunity. *Ann Rheum Dis* 2008; 67 Suppl 3: ii26-ii29 [PMID: 19022809 DOI: 10.1136/ard.2008.098004]

20 Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Annu Rev Immunol* 2009; 27: 485-517 [PMID: 19132915 DOI: 10.1146/annurev.immunol.082008.093925]

21 Miossec P. Diseases that may benefit from manipulating the Th17 pathway. *Eur J Immunol* 2009; 39: 667-669 [PMID: 19283719 DOI: 10.1002/eji.2009309088]

22 Yang J, Li M, Zhang H, Hong L, Feng F, Pan F, Wang Y, Wang W. Application of a self-made swivel intravenous transfusion device in constructing allogenic small bowel transplantation rejection model in rats. *Transplant Proc* 2009; 41: 4397-4400 [PMID: 20050407 DOI: 10.1111/j.1397-5215.2009.012710]

23 Yang J, Hong L, Wang W, Zhang H. A novel monoclonal antibody specific to mouse IL-17. *Hybridoma (Larchmt)* 2011; 30: 287-289 [PMID: 21707364 DOI: 10.1089/hyb.2011.0005.]

24 Wu T, Abu-Elmagd K, Bond G, Nalesnik MA, Randhawa P, Demetris AJ. A schema for histologic grading of small intestine allograft acute rejection. *Transplantation* 2003; 75: 1241-1248 [PMID: 12717210]

25 Yuan X, Paez-Cortez J, Schmitt-Knollsa I, D’Addio F, Mfar rej R, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. *J Exp Med* 2008; 205: 3133-3144 [PMID: 19047438 DOI: 10.1084/jem.20081937]

26 Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol* 2007; 25: 921-952 [PMID: 17201677 DOI: 10.1146/annurev.immunol.25.022006.141577]

27 Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeke EK, Meys I, Bullens DM, Dilissen E, Luyts L, Van Raemdonck DE, Verleden GM. The role of interleukin-17 during acute rejection after lung transplantation. *Eur Respir J* 2006; 27: 779-787 [PMID: 16585806 DOI: 10.1183/09031936.00019405]

28 Shilling RA, Wilkes DS. Role of Th17 cells and IL-17 in lung transplant rejection. *Semin Immunopathol* 2011; 33: 129-134 [PMID: 21279808 DOI: 10.1007/s00281-011-0257-9]

29 Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. *Blood* 2009; 113: 1365-1374 [PMID: 19857685 DOI: 10.1182/blood-2008-06-164240]

30 Maurer N, Burian J, von Garnier C, D¨nrhofer S, Ger mano D, Schuett C, Tammi M, Bingisser R, Erikssoon U, Hunziker L. Interferon-gamma regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease. *An J Respir Crit Care Med* 2008; 178: 379-388 [PMID: 18517101 DOI: 10.1164/rccm.200711-1648OC]

31 Chen H, Wang W, Xie H, Xu X, Wu J, Jiang Z, Zang M, Zhou L, Zheng S. A pathogenic role of IL-17 at the early stage of corneal allograft rejection. *Transplant Immunol* 2009; 21: 155-161 [PMID: 19358887 DOI: 10.1016/j.trim.2009.03.004]

32 Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. *Immunol Rev* 2008; 223: 87-113 [PMID: 18613831 DOI: 10.1111/j.1600-065X.2008.00628.x]

33 Miossec P. IL-17 and Th17 cells in human inflammatory diseases. *Microbes Infect* 2009; 11: 625-630 [PMID: 19377191 DOI: 10.1016/j.micinf.2009.04.003]

34 Hsieh HG, Loong CC, Lui WY, Chen A, Lin CY. IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection. *Transplant Int* 2001; 14: 287-298 [PMID: 11692212 DOI: 10.1111/j.1399-0607.2000.00062.x]

35 Itoh S, Nakae S, Axtell RC, Velotta JB, Kimura N, Kajiwara N, Iwakura Y, Saito H, Adachi H, Steinman L, Robbins RC, Fischbein MP. IL-17 contributes to the development of chronic rejection in a murine heart transplant model. *J Clin Immunol* 2010; 30: 235-240 [PMID: 20130970 DOI: 10.1007/s10875-009-9366-9]

36 Acosta-Rodriguez EV, Napolitani L, Ganzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol* 2007; 8: 942-949 [PMID: 17676045 DOI: 10.1038/nii1496]

37 Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat Immunol* 2007; 8: 950-957 [PMID: 17676044 DOI: 10.1038/nii1497]